Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$22.26 USD
+0.76 (3.53%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $22.28 +0.02 (0.09%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Brokerage Reports
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 61 - 80 ( 192 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Inhale Ensifentrine, Exhale COPD''s Next Blockbuster; Assuming at OP & $27 PT
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
First Pivotal Readout Delivers; Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Positive ENHANCE-2 Results; ENHANCE-1 Data Around YE; Q2 Financials
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
KOL Event Highlights Ensifentrine Value Proposition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
KOL Event Highlights: Momentum Building Ahead of ENHANCE-2 Data in Q3
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
ENHANCE-1 Enrollment Completed; Data Timelines Reconfirmed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
ENHANCE-1 Enrollment Complete, Counting Down to Topline ENHANCE-2 Data in Q3
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
ENHANCE Enrollment Progress; 1Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q1: ENHANCE Program Nears Completed Enrollment, Eyes on ENHANCE-2 Data in Q3
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Highlights from COPD Landscape KOL Call: New Kid on the Block Goes For the GOLD
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Key Takeaways from Virtual NDR; Wedbush hosts COPD KOL Call on April 13
Provider: Wedbush Securities Inc.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Ensifentrine Pivotal Program Advances Apace; 2021 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q4/FY21: Focus Remains on ENHANCE-2 Data in Q3:22, ENHANCE-1 Around YE:22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L